Hepatology International

, Volume 7, Issue 2, pp 437–442 | Cite as

Current management and recommendations on hepatitis B therapy in HIV-coinfected patients

  • Lionel Piroth
  • Sophie Mahy
  • Stanislas Pol
  • Fabrice Carrat
  • Damien Sene
  • Manuel Etienne
  • Caroline Lascoux-Combe
  • Anne Simon
  • Jean-Luc Schmit
  • Patrice Cacoub
  • For the GERMIVIC Study Group
Original Article



The match between the real-life therapeutic management of chronic hepatitis B (CHB) in HIV-infected patients and the recommendations that existed at the time has never been assessed on a case-by-case basis.


A total of 73 HBV–HIV coinfected patients, 34 of whom were first followed in 2003–2005 and 39 in 2006–2008 (before and after the 2005 European Consensus Conference on the treatment of chronic viral hepatitis in HIV coinfected patients), were included. All the data were retrospectively collected from their first visit to October 2008 through a standardised questionnaire.


Baseline HBV DNA quantification and/or liver histology were missing in 44.1 and 28.2% of cases before and after 2005, respectively (p = 0.16). The observed management significantly differed from the recommendations for the whole population (p = 0.009), for the 2003–2005 group (p = 0.02), and tended to differ for the 2006–2008 group (p = 0.07). Therapeutic management of CHB was in accordance with the recommendations in 27 (57.4%) cases, with a higher rate of untreated patients in the 2003–2005 group, and a high rate of patients on dual therapy in both groups despite the fact that HBV therapy was not recommended.


Even though global management of HBV–HIV coinfected patients is improving, baseline evaluation of CHB though necessary is still often insufficient. The strong rationale for early dual anti-HIV and anti-HBV therapy, and the reality of everyday clinical practice, bring support to the recent simplification of the recommendations widening the use of tenofovir and emtricitabine in HBV–HIV coinfected patients, irrespective of immunological, virological, or histological considerations.


HIV HBV Management Guidelines 


  1. 1.
    Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615–624PubMedCrossRefGoogle Scholar
  2. 2.
    Larsen C, Pialoux G, Salmon D, et al. Prévalence des coinfections par les virus des hépatites B et C dans la population VIH+, France, juin 2004. BEH 2005;23:109–112Google Scholar
  3. 3.
    Piroth L, Pol S, Lacombe K, et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010;53:1006–1012Google Scholar
  4. 4.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–242CrossRefGoogle Scholar
  5. 5.
    McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006;101:S7–S12PubMedCrossRefGoogle Scholar
  6. 6.
    Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921–1926PubMedCrossRefGoogle Scholar
  7. 7.
    Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006;44:S65–S70PubMedCrossRefGoogle Scholar
  8. 8.
    Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009;23:1881–1889PubMedCrossRefGoogle Scholar
  9. 9.
    Bonacini M, Louie S, Bzowej N, Wohl A. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004;18(15):2039–2045Google Scholar
  10. 10.
    Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006;44:S25–S27PubMedCrossRefGoogle Scholar
  11. 11.
    Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003;4:241–249PubMedCrossRefGoogle Scholar
  12. 12.
    Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004;18:1169–1177PubMedCrossRefGoogle Scholar
  13. 13.
    Sheng W, Chen M, Hsieh S, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004;38:1471–1477PubMedCrossRefGoogle Scholar
  14. 14.
    Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006;44:S132–S139PubMedCrossRefGoogle Scholar
  15. 15.
    Carr A, Cooper D. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;349:995–996PubMedCrossRefGoogle Scholar
  16. 16.
    Bessesen M, Ives D, Condreay L, Lawrence S, Sherman K. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032–1035PubMedCrossRefGoogle Scholar
  17. 17.
    Lacombe K, Boyd A, Gozlan J, Lavocat F, Girard PM, Zoulim F. Drug-resistant and immune-escape HBV mutants in HIV-infected hosts. Antivir Ther 2010;15:493–497PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2011

Authors and Affiliations

  • Lionel Piroth
    • 1
  • Sophie Mahy
    • 1
  • Stanislas Pol
    • 2
  • Fabrice Carrat
    • 3
  • Damien Sene
    • 4
    • 5
  • Manuel Etienne
    • 6
  • Caroline Lascoux-Combe
    • 7
  • Anne Simon
    • 8
  • Jean-Luc Schmit
    • 9
  • Patrice Cacoub
    • 4
    • 5
  • For the GERMIVIC Study Group
  1. 1.Département d’ InfectiologieCHU Dijon and Université de BourgogneDijon CedexFrance
  2. 2.Service d’ Hépatologie, AP-HP, Hôpital CochinParisFrance
  3. 3.Faculté de Médecine Saint Antoine, Inserm U707ParisFrance
  4. 4.AP-HP, Hôpital Pitié-SalpêtrièreParisFrance
  5. 5.Université Pierre et Marie Curie, CNRS, UMR 7087ParisFrance
  6. 6.Service de Maladies Infectieuses, CHU RouenRouenFrance
  7. 7.CHU, Saint LouisParisFrance
  8. 8.Service de Médecine Interne, AP-HP, Hôpital Pitié-SalpêtrièreParisFrance
  9. 9.Service de Maladies Infectieuses, CHU AmiensAmiensFrance

Personalised recommendations